European Archives - Page 556 of 1590 - European Medical Journal

Predicting Methotrexate Failure in Ectopic Pregnancy

A new retrospective study has identified key risk factors for methotrexate (MTX) treatment failure in tubal ectopic pregnancy (TEP). The findings suggest that higher gravidity and elevated β-hCG levels increase the likelihood of treatment failure, while additional MTX doses improve success rates.

Scientists Identify Genetic Variants That Drive Cancer Risk and Growth

Researchers uncover genetic variants that drive cancer risk, revealing new therapeutic targets and refining genetic screening strategies.

The Second Brain: Transforming Gut Healing: Part 2

In this second part of the podcast, Jonathan welcomes back Douglas Drossman, pioneer in disorders of gut-brain interaction.

STI Surge in Europe Sparks Public Health Concern

The ECDC’s Annual Epidemiological Reports analysed surveillance data from 29 EU/EEA countries, tracking trends in gonorrhoea, syphilis, and chlamydia.

Coeliac Disease Risk Drops with High-Fibre Diet in Infants

A new study suggests that infants who consume a high-fibre diet before their first birthday may have a significantly lower risk of developing celiac disease.

Which Treatment for Basal Cell Carcinoma is More Effective?

After five years, the probability of remaining free from treatment failure was 77.8% for patients who underwent superficial curettage.

FDA fast-tracks Boehringer's NSCLC drug review

The FDA has granted priority review to zongertinib for non-small cell lung cancer (NSCLC).

OCEAN(a)-DOSE Trial: New Data on Lipoprotein(a) and Oxidised Phospholipids

Olpasiran significantly lowers oxidized phospholipids on apolipoprotein B but has no impact on systemic inflammatory markers in cardiovascular disease.

New Study Explores ctDNA in Urothelial Cancer Treatment

Researchers aimed to establish a plasma ctDNA sequencing assay and evaluate its effectiveness in assessing tumour genetics and treatment response.

Rezivertinib Outperforms Gefitinib in NSCLC Treatment Study

A Phase III trial has shown that rezivertinib offers superior progression-free survival compared to gefitinib as a first-line treatment in EGFR-mutated locally advanced or metastatic non-small-cell lung cancer.